مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

10
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

2
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Pulmonary Arterial Hypertension Induced by Immune Checkpoint Combined Therapy in an Intrahepatic Cholangiocarcinoma Patient: A Case Report

Pages

  240-246

Abstract

 Immune Checkpoint Inhibitors (ICIs) have dramatically revolutionized the therapeutic approaches by which we treat a series of cancers accompanied by Immune-Related Adverse Events (irAEs). Herein, we reported an Intrahepatic Cholangiocarcinoma male patient with a history of Ankylosing Spondylitis developing Pulmonary Arterial Hypertension (PAH) under ICI combined therapy with pembrolizumab and lenvatinib. The indirect measurement of cardiac ultrasound showed a pulmonary artery pressure (PAP) of 72mmHg after 21 three-week cycles of ICI combined therapy. The patient partially responded to the treatment of glucocorticoid and mycophenolate mofetil. The PAP decreased to 55mmHg 3 months after the ICI combined therapy was discontinued, but increased to 90mmHg after the ICI combined therapy was rechallenged. We treated him with adalimumab-an antitumor necrosis factoralpha (ani-TNF-α, ) antibody-combined with glucocorticoid and immunosuppressants under lenvatinib monotherapy. The patient responded again with PAP decreasing to 67mmHg after 2 two-week cycles of adalimumab. Accordingly, we diagnosed him to have irAE-related PAH. Our findings supported the use of glucocorticoid disease-modifying antirheumatic drugs (DMARDs) as a treatment option in refractory PAH.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    ZHANG, JINGJING, Zhang, Shasha, Xu, Shuo, Zhang, Xiaoyun, Li, Jiasong, Ji, Zhengzheng, Liu, Qingyi, & Guo, Zhanjun. (2023). Pulmonary Arterial Hypertension Induced by Immune Checkpoint Combined Therapy in an Intrahepatic Cholangiocarcinoma Patient: A Case Report. IRANIAN JOURNAL OF IMMUNOLOGY (IJI), 20(2), 240-246. SID. https://sid.ir/paper/1145608/en

    Vancouver: Copy

    ZHANG JINGJING, Zhang Shasha, Xu Shuo, Zhang Xiaoyun, Li Jiasong, Ji Zhengzheng, Liu Qingyi, Guo Zhanjun. Pulmonary Arterial Hypertension Induced by Immune Checkpoint Combined Therapy in an Intrahepatic Cholangiocarcinoma Patient: A Case Report. IRANIAN JOURNAL OF IMMUNOLOGY (IJI)[Internet]. 2023;20(2):240-246. Available from: https://sid.ir/paper/1145608/en

    IEEE: Copy

    JINGJING ZHANG, Shasha Zhang, Shuo Xu, Xiaoyun Zhang, Jiasong Li, Zhengzheng Ji, Qingyi Liu, and Zhanjun Guo, “Pulmonary Arterial Hypertension Induced by Immune Checkpoint Combined Therapy in an Intrahepatic Cholangiocarcinoma Patient: A Case Report,” IRANIAN JOURNAL OF IMMUNOLOGY (IJI), vol. 20, no. 2, pp. 240–246, 2023, [Online]. Available: https://sid.ir/paper/1145608/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button